Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.
Andrea Eleazar, MHS
Advertisement
Articles by Andrea Eleazar, MHS
A survival analysis stratified by demographic and clinical characteristics revealed an OS benefit was observed with across key subgroups.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Toripalimab Meets Primary End Points in Nonsquamous NSCLC
2
FDA Approves Updated Cosibelimab Label in Cutaneous Squamous Cell Carcinoma
3
ONCOLOGY Editorial Advisory Board Member Dies from Glioblastoma
4
Zanidatamab Shows Meaningful Benefit in HER2+ Biliary Tract Cancer
5
